Pain management

Anesthesiology Clinics of North America

Volumn 24, Issue 1, 2006, Pages 19-37

  De Pinto, Mario ^a   Dunbar, Peter J ^a   Edwards, W Thomas ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBAMAZEPINE; CISPLATIN; CITALOPRAM; FENTANYL; GABAPENTIN; HYDROMORPHONE; KETAMINE; LAMOTRIGINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHADONE; MEXILETINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORTRIPTYLINE; OXCARBAZEPINE; OXYCODONE; PAMIDRONIC ACID; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VENLAFAXINE; VINCRISTINE; ZOLEDRONIC ACID; ZONISAMIDE;

ANALGESIA; ANALGESIC AGENT ABUSE; ANOREXIA; ANTINOCICEPTION; APPLICATION SITE DISCOMFORT; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CARDIOTOXICITY; CELIAC PLEXUS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DELIRIUM; DIZZINESS; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; GANGLION BLOCK; HALLUCINATION; HUMAN; HYPOGASTRIC PLEXUS; INTRACTABLE PAIN; NAUSEA AND VOMITING; NERVE BLOCK; NEUROPATHIC PAIN; NOCICEPTION; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; REVIEW; SPINAL CORD STIMULATION; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TREMOR; TRIGEMINUS NEURALGIA; UNPLEASANT DREAM; UNSPECIFIED SIDE EFFECT; UNSTEADINESS; VISCERAL PAIN; WORLD HEALTH ORGANIZATION;

ADJUVANTS, ANESTHESIA; ANALGESICS, OPIOID; ELECTRIC STIMULATION THERAPY; NERVE BLOCK; PAIN; PALLIATIVE CARE;

EID: 32644433182     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2005.12.006     Document Type: Review

References (115)

1. World Health Organization Cancer pain relief 1986 WHO Geneva (Switzerland)
2. S. Grond, D. Zech, and S.A. Schug Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life J Pain Symptom Manage 6 1991 411 422
3. S. Grond, D. Zech, and J. Lynch Validation of World Health Organization guidelines for pain relief in head and neck cancer Ann Otol Rhinol Laryngol 102 1993 342 348
4. S. Grond, D. Zech, and J. Lynch Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study Pain 63 1995 65 76
5. A.R. Jadad, and G. Browman The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation JAMA 274 1995 1870 1873
6. C.S. Cleeland, R. Gonin, and A.K. Hatfield Pain and its treatment in outpatients with metastatic cancer N Engl J Med 330 1994 592 596
7. F. Larue, S.M. Colleau, and L. Brasseur Multicentre study of cancer pain and its treatment in France BMJ 310 1995 1034 1037
8. I.J. Higginson Innovations in assessment: epidemiology and assessment of pain in advanced cancer T.S. Jensen J.A. Turner Z. Wiesenfeld-Hallin Proceedings of the 8th World Congress on Pain: Progress in Pain Research and Management 1997 IASP Press Seattle (WA) 707 716
9. A. Banning, P. Sjogren, and H. Henriken Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic Pain 45 1991 45 48
10. J.A. Billings Recent advances: palliative care BMJ 321 2000 555 558
11. G.T. Linlater, M.E. Leng, and E.J. Tiernan Pain management services in palliative care: a national survey Palliat Med 16 2002 435 439
12. C.L. Stucky, M.S. Gold, and X. Zhang Mechanisms of pain Proc Natl Acad Sci U S A 98 2001 11845 11846
13. A.H. Dickenson Spinal pharmacology of pain Br J Anaesth 75 1995 193 200
14. K. Elliott, N. Minami, and Y. Kolesnikov The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu opioid morphine but not to the kappa opioids Pain 56 1994 69 75
15. World Health Organization Cancer pain relief: report of a WHO Expert Committee 1996 WHO Geneva (Switzerland)
16. G.W. Hanks, F. de Conno, N. Cherny for the Expert Working Group of the Research Network of the European Association for Palliative Care Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 5 2001 587 593
17. H. McQuay Opioids in pain management Lancet 353 1999 2229 2232
18. N.A. Hagen, M. Thirlwell, and J. Eisenhoffer Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled release morphine (MS Contin XL) in cancer pain J Pain Symptom Manage 29 1 2005 80 90
19. J.G. Liu, X.P. Liao, and Z.H. Gong The difference between methadone and morphine in regulation of delta opioid receptor underlies the antagonistic effect of methadone on morphine mediated cellular actions Eur J Pharmacol 374 1999 233 239
20. E. Bruera, S. Watanabe, and R. Fainsinger Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain Pain 62 1995 141 146
21. M. Nilsson, V. Meresaar, and E. Anggard Clinical pharmacokinetics of methadone Acta Anaesthesiol Scand Suppl 74 1982 66 69
22. G.D. Bellward, P.M. Warren, and W. Harold Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses Clin Pharmacol Ther 22 1977 92 99
23. A. Davis, and C. Inturrisi d-Methadone blocks morphine tolerance and N-methyl-d-aspartate induced hyperalgesia J Pharmacol Exp Ther 289 1999 1048 1053
24. C.B. Eap, G. Bertschy, and P. Baumann High interindividual variability of methadone enantiomer blood levels to dose ratios Arch Gen Psychiatry 55 1998 89 90
25. E. Bruera, J.L. Palmer, and S. Bosnjak Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study J Clin Oncol 22 1 2004 185 192
26. S. Mercadante, A. Casuccio, and F. Fulfaro Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study J Clin Oncol 19 2001 2898 2904
27. C. Scholes, N. Gotmy, and I. Trotman Methadone titration in opioid resistant cancer pain Eur J Cancer Care (Engl) 8 1999 26 29
28. M.P. Davis, J. Varga, and D. Dickerson Normal release and controlled release oxycodone: pharmacokinetics, pharmacodynamics, and controversy Support Care Cancer 11 2003 84 92
29. R. Poyhia, A. Vainio, and E. Kalso A review of oxycodone's clinical pharmacokinetics and pharmacodynamics J Pain Symptom Manage 8 1993 63 67
30. R. Poyhia, R. Seppala, and K.T. Olkkola The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects Br J Pharmacol 33 1992 617 621
31. R.F. Kaiko, D.P. Benziger, and R.D. Fitzmartin Pharmacokinetic- pharmacodynamic relationships of controlled release oxycodone Clin Pharmacol Ther 59 1996 52 61
32. F.B. Ross, S.C. Wallis, and M.T. Smith Co-administration of sub-antinociceptive synergy with reduced CNS side effects in rats Pain 84 2000 421 428
33. J.W. Mandema, R.F. Kaiko, and B. Oshlak Characterization and validation of a pharmacokinetic model for controlled release oxycodone Br J Clin Pharmacol 42 1996 747 756
34. R. Kaplan, W.C. Parris, and M.L. Citron Comparison of controlled release and immediate release oxycodone tablets in patients with cancer pain J Clin Oncol 16 1998 3230 3237
35. R.T. Salzman, M.S. Roberts, and J. Wild Can a controlled release oral dose form of oxycodone be used as readily as an immediate release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 18 1999 271 279
36. G.R. Lauretti, G.M. Oliveira, and N.L. Pereira Comparison of sustained release morphine with sustained release oxycodone in advanced cancer patients Br J Cancer 89 2003 2027 2030
37. A. Spake Not an appropriate use: did the makers of oxycontin push too hard? US News World Rep 131 2001 26
38. N. Sarhill, D. Walsh, and K.A. Nelson Hydromorphone: pharmacology and clinical applications in cancer patients Support Care Cancer 9 2001 84 96
39. P.V. Parab, W.A. Ritschel, and D.E. Coyle Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects Biopharm Drug Dispos 9 1988 187 199
40. B.A. Coda, A. Tanaka, and R.C. Jacobson Hydromorphone analgesia after intravenous bolus administration Pain 71 1997 41 48
41. H.F. Hill, B.A. Coda, A. Tanaka, and R. Schaffer Multiple dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects Anesth Analg 72 1991 330 336
42. E. Bruera, P. Sloan, B. Mount for the Canadian Palliative Care Clinical Trials Group A randomized, double blind, double dummy, crossover trial comparing the safety and efficacy of oral sustained release hydromorphone with immediate release hydromorphone in patients with cancer pain J Clin Oncol 14 1996 1713 1717
43. N.D. De Stoutz, E. Bruera, and M. Suarez-Almazor Opioid rotation for toxicity reduction in terminal cancer patients J Pain Symptom Manage 10 1995 378 384
44. T.L. Skaer Practice guidelines for transdermal opioids in malignant pain Drugs 64 23 2004 2629 2638
45. G. Hanks Oral transmucosal fentanyl citrate for the management of breakthrough pain J Palliat Care 8 2001 6 9
46. R. Payne, S. Chandler, and M. Einhaus Guidelines for the clinical use of transdermal fentanyl Anticancer Drugs 6 3 1995 50 53
47. L. Radbruch, and F. Elsner Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany Keio J Med 53 1 2004 23 29
48. G. Hanks Oral transmucosal fentanyl citrate for the management of breakthrough pain J Palliat Care 8 2001 6 9
49. B. Donner, M. Zenz, and M. Tryba Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain Pain 64 3 1996 527 534
50. S. Ahmedzai, and D. Brooks Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy, and quality of life: TTS-fentanyl Comparative Trial Group J Pain Symptom Manage 13 5 1996 254 261
51. D. Lussier, A.G. Huskey, and R.K. Portenoy Adjuvant analgesics in cancer pain management Oncologist 9 5 2004 571 591
52. R.H. Dworkin, M. Backonja, and M.C. Rowbotham Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations Arch Neurol 60 2003 1524 1534
53. A. Caraceni, E. Zecca, and C. Bonezzi Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group J Clin Oncol 22 14 2004 2909 2917
54. C. Menigaux, F. Adam, and B. Guignard Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery Anesth Analg 100 5 2005 1394 1399
55. M.M. Backonja Anticonvulsants (antineuropathics) for neuropathic pain syndromes Clin J Pain 16 Suppl 2 2000 S67 S72
56. A.H. Glassman, and J.T. Bigger Jr Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review Arch Gen Psychiatry 38 1981 815 820
57. S.H. Sindrup, L.F. Gram, and K. Brosen The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms Pain 42 1990 135 144
58. S.H. Sindrup, F.W. Bach, and C. Madsen Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial Neurology 60 2003 1284 1289
59. T. Tasmuth, B. Hartel, and E. Kalso Venlafaxine in neuropathic pain following treatment of breast cancer Eur J Pain 6 2002 17 24
60. W.G. Brose, and M.J. Cousins Subcutaneous lidocaine for treatment of neuropathic cancer pain Pain 45 1991 145 148
61. R.W. Campbell Mexiletine N Engl J Med 316 1987 29 34
62. N. Ellison, C.L. Loprinzi, and J. Kugler Phase III placebo controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients J Clin Oncol 15 1997 2974 2980
63. J. Szanto, N. Ady, and S. Jozsef Pain killing with calcitonin nasal spray in patients with malignant tumors Oncology 49 1992 180 182
64. D. Glover, A. Lipton, and A. Keller Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose seeking study Cancer 74 1994 2949 2955
65. L.S. Rosen, D. Gordon, and M. Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blind, comparative trial Cancer J 7 2001 377 387
66. G.N. Hortobagyi, R.L. Theriault, and L. Porter Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases N Engl J Med 335 1996 1785 1791
67. A. Lipton, E. Small, and F. Saad The new biphosphonate Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate Cancer Invest 20 Suppl 2 2002 S45 S54
68. A.A. Weinbroum, B. Bender, and J. Bickels Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient controlled epidural analgesia requirement: a randomized, placebo controlled, double blind study in lower body bone malignancy operated patients Cancer 97 2003 2334 2340
69. M.L. Cohen, S.L. Chan, W.L. Way, and A.J. Trevor Distribution in brain and metabolism of ketamine in the rat after intravenous administration Anesthesiology 39 1973 370 376
70. I.S. Grant, W.S. Nimmo, and J.A. Clements Pharmacokinetics and analgesic effects of IM and oral ketamine Br J Anesth 53 1981 805 810
71. M. Shimoyama, N. Shimoyama, and A.L. Gorman Oral ketamine is antinociceptive in the rat formalin test: role of metabolite norketamine Pain 81 1999 85 93
72. P.K. Eide, A. Stubaugh, and I. Oye Continuous subcutaneous administration of N-methyl-d aspartic acid (NMDA) receptor antagonist ketamine in the treatment of postherpetic neuralgia Pain 61 1995 221 228
73. C.F. Stannard, and G.E. Porter Ketamine hydrochloride in the treatment of phantom limb pain Pain 54 1993 227 230
74. J. Persson, G. Axelsson, and R.G. Hallin Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization Pain 60 1995 217 222
75. G.R. Lauretti, I.C.P.R. Lima, and M.P. Reis Oral ketamine and transdermal nitroglycerine as analgesic adjuvants to oral morphine therapy for cancer pain management Anesthesiology 90 1999 1528 1533
76. T.R. Kannan, A. Saxena, and S. Bhatnagar Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients J Pain Symptom Manage 23 1 2002 60 65
77. I.W. Birkel Jr, and D.K. Clawson Drug combinations with orphenadrine for pain relief associated with muscle spasm Clin Pharmacol Ther 9 1968 639 646
78. G.H. Fromm Baclofen as an adjuvant analgesic J Pain Symptom Manage 9 1994 500 509
79. T. Meuser, C. Pietruck, and L. Radbruch Symptoms during cancer pain treatment following WHO guidelines: a longitudinal follow-up study of symptoms prevalence, severity, and etiology Pain 93 2001 247 257
80. F.M. Ferrante, M. Bedder, and R.A. Caplan Practice guidelines for cancer pain management Anesthesiology 84 1996 1243 1257
81. M.D. Bedder, K. Burchiel, and A. Larson Cost analysis of two implantable narcotic delivery systems J Pain Symptom Manage 6 1991 368 373
82. A.W. Burton, A. Rajagopal, and H.N. Shah Epidural and intrathecal analgesia is effective in treating refractory cancer pain Pain Med 5 3 2004 239 247
83. A.W. Burton, and S.J. Hassenbusch The double catheter technique for intrathecal medication trial: a brief technical note and report of five cases Pain Med 2 2001 352 354
84. J. Eisenach, S. DuPen, M. Dubois for the Epidural Clonidine Study Group Epidural clonidine analgesia for intractable cancer pain Pain 61 1995 391 399
85. K. Souter, J. Davies, and J. Loeser Continuous intrathecal meperidine for severe refractory cancer pain: a case report Clin J Pain 21 2 2005 193 196
86. T.J. Smith, P.S. Staats, and T. Deer Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival J Clin Oncol 20 19 2002 4040 4049
87. K. Kumar, C. Toth, and R.K. Hath Epidural spinal cord stimulation for treatment of chronic pain; some predictors of success: a 15 year experience Surg Neurol 50 1998 110 121
88. B. Linderoth, and R. Foreman Physiology of spinal cord stimulation: review and update Neuromodulation 2 1999 150 164
89. J.G. Cui, W.T. O'Connor, and U. Ungerstedt Spinal cord stimulation attenuates augmented dorsal horn release of excitatory aminoacids in mononeuropathy via a GABAergic mechanism Pain 73 1997 87 95
90. C.N. Shealy, J.T. Mortimer, and J.B. Reswick Electrical inhibition of pain by stimulation of the dorsal columns: preliminary clinical report Anesth Analg 4 1967 489 491
91. A.D. Kay, M.D. McIntyre, and W.A. Macrae Spinal cord stimulation: a long term evaluation in patients with chronic pain Br J Neurosurg 15 2001 335 341
92. H. Harke, P. Gretenkort, and H.U. Ladleif Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain Anesth Analg 94 2002 694 700
93. K.M. Alo', and J. Olsheimer New trends in neuromodulation for the management of neuropathic pain Neurosurgery 50 2002 690 702
94. E.K. Rowinsky, V. Chaudry, and D.R. Cornblath Neurotoxicity of taxol J Natl Cancer Inst Monogr 15 1993 107 115
95. S.W. Thompson, L.E. Davis, and L.E. Kornfeld Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies Cancer 54 1984 1269 1275
96. S. Quasthoff, and H.P. Hartung Chemotherapy induced peripheral neuropathy J Neurol 249 2002 9 17
97. P.A. Forsyth, C. Balmaceda, and K. Peterson Prospective study of paclitaxel induced peripheral neuropathy with quantitative sensory testing J Neurooncol 35 1997 47 53
98. J.P. Cata, J.V. Cordella, and A.W. Burton Spinal cord stimulation relieves chemotherapy induced pain; a clinical case report J Pain Symptom Manage 27 1 2004 72 78
99. O.A. de Leon Casasola Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain Cancer Control 7 2 2000 142 148
100. S. Ischia, A. Ischia, and E. Polati Three posterior percutaneous celiac plexus block techniques; a prospective randomized study in 61 patients with pancreatic cancer pain Anesthesiology 76 1992 534 540
101. E. Eisenberg, D.B. Carr, and T.C. Chalmers Neutolytic celiac plexus block for treatment of cancer pain: a meta-analysis Anesth Analg 80 1995 290 295
102. D.C. Moore, W.H. Bush, and L.I. Burnett Celiac plexus block; a roentgenographic anatomic study of technique and spread of solution in patients and corpses Anesth Analg 60 1981 369 379
103. A. Montero Matamala, F. Vidal Lopez, and L. Martinez Inaraja The percutaneous anterior approach to the celiac plexus using CT guidance Pain 34 1988 285 288
104. R.P. Lieberman, and S.D. Waldman Celiac plexus neurolysis with the modified transaortic approach Radiology 175 1990 274 276
105. M. De Cicco, M. Matovic, and R. Bortolussi Celiac plexus block: injectate spread and pain relief in patients with regional anatomic distortions Anesthesiology 94 4 2001 561 565
106. S. Ischia, E. Polati, and G. Finco Labat lecture: the role of the neurolytic celiac plexus block in pancreatic cancer pain management: do we have the answers? Reg Anesth Pain Med 23 1998 611 614
107. J.P. Rathmell, J.M. Gallant, and D.L. Brown Computed tomography and the anatomy of celiac plexus block Reg Anesth Pain Med 25 4 2000 411 416
108. G.Y. Wong, and D.L. Brown Transient paraplegia following alcohol celiac plexus block Reg Anesth Pain Med 20 1995 352 355
109. R. Plancarte, C. Amescua, and R.B. Patt Superior hypogastric plexus block for pelvic cancer pain Anesthesiology 73 1990 236 239
110. O.A. de Leon Casasola, and E. Kent Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer Pain 54 1993 145 151
111. R. Plancarte, O.A. de Leon Casasola, and M. El Helaly Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer Reg Anesth Pain Med 22 1997 562 568
112. M.J. Lema, D.P. Myers, and O.A. de Leon Casasola Pleural phenol therapy for the treatment of chronic esophageal cancer pain Reg Anesth Pain Med 17 1992 166 170
113. K.E. Stromskag, F. Reiestad, and E.L. Holmqvist Intrapleural administration of 0.25%, 0.375%, and 0.5% bupivacaine with epinephrine after cholecystectomy Anesth Analg 67 1988 430 444
114. F. Marinangeli, A. Ciccozzi, and M. Leonardis Use of strong opioids in advanced cancer pain: a randomized trial J Pain Symptom Manage 27 5 2004 409 416
115. K.M. Foley, and R.W. Houde Methadone in cancer pain management: individualize dose and titrate to effect J Clin Oncol 16 1998 3213 3215